Telix Pharmaceuticals Limited
TLPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 55.8% | 213.9% | 2,007.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | -$0 |
| % Margin | 65.1% | 62.6% | 18.3% | -391.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | -$0 | -$0 |
| % Margin | 10.5% | 10.3% | -57.4% | -1,069.6% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 6.4% | 1% | -65% | -1,059.9% |
| EPS | 0.15 | 0.016 | -0.34 | -0.29 |
| % Growth | 820.2% | 104.8% | -17.2% | – |
| EPS Diluted | 0.14 | 0.016 | -0.34 | -0.29 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 12.5% | 4.6% | -58% | -922.5% |